DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth

Information source: Yale University
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Obesity; Impaired Glucose Tolerance; Type 2 Diabetes Mellitus

Intervention: Rosiglitazone (Drug); Placebo (Drug)

Phase: N/A

Status: Completed

Sponsored by: Yale University

Official(s) and/or principal investigator(s):
Sonia Caprio, MD, Principal Investigator, Affiliation: Yale School of Medicine Department of Pediatric Endocrinology

Summary

The purpose of the study is to determine whether treatment of children and adolescents with Impaired Glucose Tolerance (IGT) with rosiglitazone will lead to improvements in insulin sensitivity and glucose tolerance.

Clinical Details

Official title: Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Primary outcome:

Mean Percent Change From Baseline in Whole-body Insulin Sensitivity

Mean Percent Change in Visceral-to-subcutaneous Abdominal Fat

Percentage of Subjects Who Converted Impaired Glucose Tolerance (IGT) to Normal Glucose Tolerance (NGT)

Mean Percent Change From Baseline in Hepatic Fat Fraction (HFF)

Secondary outcome: Mean Percent Change From Baseline in Adiponectin

Detailed description: Impaired Glucose Tolerance (IGT) is a prelude to diabetes, which is increasing in prevalence in obese children and adolescents with marked obesity. This condition tends to progress to Type 2 Diabetes Mellitus (T2DM) at an alarmingly rapid tempo. The increased prevalence of childhood and adolescent obesity and greater risk of IGT, and progression to diabetes, in this population set the stage for a series of studies aimed at understanding the metabolic phenotype and natural history of pre-diabetes in obese youth. The investigators found that obese children and adolescents with IGT are characterized by marked insulin resistance related to altered lipid partitioning, favoring lipid deposition in the visceral and intramyocellular compartment. Furthermore, the investigators found an impairment of the acute insulin response in these youngsters. Follow-up revealed a rapid deterioration from IGT to frank diabetes. Based on these studies, there is a strong rationale for changing the balance between visceral and subcutaneous fat and muscle lipid content in a more favorable pattern in order to improve insulin sensitivity. The primary objective of this study is to determine, in a group of ethnically diverse children and adolescents with IGT, whether treatment with rosiglitazone leads to improvements in insulin sensitivity and glucose tolerance. Secondary objectives are to determine whether rosiglitazone is safe and well tolerated.

Eligibility

Minimum age: 10 Years. Maximum age: 18 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Good general health

- Aged 10 to 18 yrs (females: Tanner stage II-V;and males: testes size>6ml)

- IGT based on 2-hr plasma glucose>140mg/dl and <200mg/dl during an OGTT.

Exclusion Criteria:

- Baseline creatinine>1. 0mg

- AST and ALT>2. 5 ULN

- Anemia (Hct<30)

- Pregnancy (females must have a negative urine pregnancy test during the study)

- Cardiac or pulmonary or other significant chronic illness

- Plans to increase the frequency or intensity of a regular exercise program

- Psychiatric disorder or substance abuse of anorexic agents.

Locations and Contacts

Yale School of Medicine, New Haven, Connecticut 06520, United States
Additional Information

Starting date: November 2005
Last updated: July 15, 2013

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017